Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 30, 2020 07:30 ET | Source: Zai Lab Limited

Zai Lab Announces Upcoming Presentation at 39th Annual J.P. Morgan Healthcare Conference

SHANGHAI and SAN FRANCISCO, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that...
December 28, 2020 19:00 ET | Source: Zai Lab Limited

Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List

SHANGHAI and SAN FRANCISCO, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that ZEJULA® has...
December 28, 2020 07:30 ET | Source: Zai Lab Limited

Zai Lab and Cullinan Oncology Announce Strategic Collaboration and License Agreement for CLN-081 in Greater China

- Zai Lab to lead development and commercialization of CLN-081 in Greater China - Cullinan will receive $20 million upfront, up to $211 million in future milestones, and royalties - Zai Lab to...
December 16, 2020 20:15 ET | Source: Zai Lab Limited

Zai Lab Partner MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer

MARGENZA (margetuximab-cmkb) is the first HER2-targeted therapy to have improved progression-free survival (PFS) versus Herceptin® (trastuzumab), both combined with chemotherapy, in a head-to-head...
December 01, 2020 07:30 ET | Source: Zai Lab Limited

Zai Lab Appoints Alan Sandler, M.D., as President, Head of Global Development, Oncology

SHANGHAI and SAN FRANCISCO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced the...
November 10, 2020 19:00 ET | Source: Zai Lab Limited

Zai Lab Partner Five Prime Therapeutics Announces Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free and Overall Survival Benefit Compared to Placebo Plus Chemotherapy in Front-Line Advanced Gastric or Gastroesophageal Junction Cancer

All three efficacy endpoints in the global Phase 2 FIGHT trial met pre-specified statistical significance• Median progression-free survival (PFS) improved from 7.4 months in the placebo arm to 9.5...
October 29, 2020 07:30 ET | Source: Zai Lab Limited

Zai Lab Announces First Patient Dosed in China in a Potentially Registrational Study of Retifanlimab in Patients with Endometrial Cancer

SHANGHAI and SAN FRANCISCO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial stage biopharmaceutical company, today announced dosing of the...
October 28, 2020 07:30 ET | Source: Zai Lab Limited

Zai Lab Announces Upcoming Presentations in November Investor Conferences

SHANGHAI and SAN FRANCISCO, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial stage biopharmaceutical company, today announced that...
October 09, 2020 08:48 ET | Source: Zai Lab Limited

Zai Lab Announces Full Exercise of the Over-allotment Option

SHANGHAI and SAN FRANCISCO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial stage biopharmaceutical company, announced full exercise of the...
October 06, 2020 07:30 ET | Source: Zai Lab Limited

Zai Lab Announces First Patient Dosed in Greater China in the Global Phase 2/3 MAHOGANY Study of Margetuximab in Gastric and Gastroesophageal Junction Cancer

SHANGHAI and SAN FRANCISCO, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial stage biopharmaceutical company, announced dosing of the first...